DnB Asset Management
SMMT icon

DnB Asset Management’s Summit Therapeutics SMMT Stock Holding History

DnB Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$718K Sell
49,305
-1,253
-2% -$22.2K ﹤0.01% 690
2026
Q1 		$959K Sell
50,558
-10,503
-17% -$170K ﹤0.01% 651
2025
Q4 		$1.07M Buy
61,061
+30,138
+97% +$567K ﹤0.01% 633
2025
Q3 		$639K Sell
30,923
-1,354
-4% -$32.8K ﹤0.01% 659
2025
Q2 		$687K Sell
32,277
-5,086
-14% -$116K ﹤0.01% 633
2025
Q1 		$721K Buy
37,363
+2,385
+7% +$47.8K ﹤0.01% 638
2024
Q4 		$624K Buy
34,978
+6,208
+22% +$120K ﹤0.01% 648
2024
Q3 		$630K Buy
+28,770
New +$402K ﹤0.01% 648

Other funds holding SMMT

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $156M AUM 183.17% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

DnB Asset Management's SMMT Position: Q2 2026 in Review

DnB Asset Management reduced its Summit Therapeutics (SMMT) stake by 2.5% in Q2 2026, selling an estimated $22.2K and leaving 49,305 shares worth $718K. The position accounts for ﹤0.01% of the portfolio, ranked #690.

DnB Asset Management first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.07M in Q4 2025. 122 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • DnB Asset Management held 49,305 shares of Summit Therapeutics worth $718K as of Q2 2026.
  • DnB Asset Management sold 1,253 Summit Therapeutics shares in Q2 2026, an estimated $22.2K.
  • Summit Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #690 holding.
  • DnB Asset Management first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • DnB Asset Management's Summit Therapeutics position peaked at $1.07M in Q4 2025.
  • 122 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.